The Delhi High Court ruled in March that pharmaceutical company Cipla can continue to sell its lung cancer drug Erlocip, a generic version of a patented drug called Tarceva, which is produced by Swiss giant Roche. The Roche drug costs US$120 a tablet, while Cipla’s generic version costs just US$40.
You must be a
subscribersubscribersubscribersubscriber
to read this content, please
subscribesubscribesubscribesubscribe
today.
For group subscribers, please click here to access.
Interested in group subscription? Please contact us.
